Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 112

1.

Role of 14-3-3σ in resistance to cisplatin in non-small cell lung cancer cells.

Cetintas VB, Tetik A, Cok G, Kucukaslan AS, Kosova B, Gunduz C, Veral A, Eroglu Z.

Cell Biol Int. 2013 Jan;37(1):78-86. doi: 10.1002/cbin.10006. Epub 2012 Nov 14.

PMID:
23339090
[PubMed - indexed for MEDLINE]
2.

Cisplatin resistance induced by decreased apoptotic activity in non-small-cell lung cancer cell lines.

Cetintas VB, Kucukaslan AS, Kosova B, Tetik A, Selvi N, Cok G, Gunduz C, Eroglu Z.

Cell Biol Int. 2012 Mar 1;36(3):261-5. doi: 10.1042/CBI20110329.

PMID:
22397496
[PubMed - indexed for MEDLINE]
3.

Suppression of STAT3 by chemically modified siRNAs increases the chemotherapeutic sensitivity of parental and cisplatin-resistant non-small cell lung cancer cells.

Tezcanli Kaymaz B, Bozok Cetintas V, Eroglu Z, Kosova B.

J BUON. 2014 Jan-Mar;19(1):145-52.

PMID:
24659656
[PubMed - indexed for MEDLINE]
4.

The 3p21.3 tumor suppressor RBM5 resensitizes cisplatin-resistant human non-small cell lung cancer cells to cisplatin.

Li P, Wang K, Zhang J, Zhao L, Liang H, Shao C, Sutherland LC.

Cancer Epidemiol. 2012 Oct;36(5):481-9. doi: 10.1016/j.canep.2012.04.004. Epub 2012 May 18.

PMID:
22609235
[PubMed - indexed for MEDLINE]
5.

Proteomics-based identification of secreted protein dihydrodiol dehydrogenase 2 as a potential biomarker for predicting cisplatin efficacy in advanced NSCLC patients.

Kuang P, Zhou C, Li X, Ren S, Li B, Wang Y, Li J, Tang L, Zhang J, Zhao Y.

Lung Cancer. 2012 Aug;77(2):427-32. doi: 10.1016/j.lungcan.2012.03.016. Epub 2012 Apr 23.

PMID:
22534668
[PubMed - indexed for MEDLINE]
6.

Bcl-XL small interfering RNA sensitizes cisplatin-resistant human lung adenocarcinoma cells.

Lei X, Huang Z, Zhong M, Zhu B, Tang S, Liao D.

Acta Biochim Biophys Sin (Shanghai). 2007 May;39(5):344-50.

PMID:
17492131
[PubMed - indexed for MEDLINE]
Free Article
7.

Copper-transporting P-type adenosine triphosphatase (ATP7A) is associated with platinum-resistance in non-small cell lung cancer (NSCLC).

Li ZH, Qiu MZ, Zeng ZL, Luo HY, Wu WJ, Wang F, Wang ZQ, Zhang DS, Li YH, Xu RH.

J Transl Med. 2012 Feb 3;10:21. doi: 10.1186/1479-5876-10-21.

PMID:
22304828
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

MKP1/CL100 controls tumor growth and sensitivity to cisplatin in non-small-cell lung cancer.

Chattopadhyay S, Machado-Pinilla R, Manguan-García C, Belda-Iniesta C, Moratilla C, Cejas P, Fresno-Vara JA, de Castro-Carpeño J, Casado E, Nistal M, Gonzalez-Barón M, Perona R.

Oncogene. 2006 Jun 1;25(23):3335-45. Epub 2006 Feb 6.

PMID:
16462770
[PubMed - indexed for MEDLINE]
9.

FoxM1 expression is significantly associated with cisplatin-based chemotherapy resistance and poor prognosis in advanced non-small cell lung cancer patients.

Wang Y, Wen L, Zhao SH, Ai ZH, Guo JZ, Liu WC.

Lung Cancer. 2013 Feb;79(2):173-9. doi: 10.1016/j.lungcan.2012.10.019. Epub 2012 Nov 20.

PMID:
23177020
[PubMed - indexed for MEDLINE]
10.

Bcl-2 downregulation sensitizes nonsmall cell lung cancer cells to cisplatin, but not to docetaxel.

Losert D, Pratscher B, Soutschek J, Geick A, Vornlocher HP, Müller M, Wacheck V.

Anticancer Drugs. 2007 Aug;18(7):755-61.

PMID:
17581297
[PubMed - indexed for MEDLINE]
11.

APE1 overexpression is associated with cisplatin resistance in non-small cell lung cancer and targeted inhibition of APE1 enhances the activity of cisplatin in A549 cells.

Wang D, Xiang DB, Yang XQ, Chen LS, Li MX, Zhong ZY, Zhang YS.

Lung Cancer. 2009 Dec;66(3):298-304. doi: 10.1016/j.lungcan.2009.02.019. Epub 2009 Mar 25.

PMID:
19324449
[PubMed - indexed for MEDLINE]
12.

Protective effects of ADAM8 against cisplatin-mediated apoptosis in non-small-cell lung cancer.

Zhang W, Wan M, Ma L, Liu X, He J.

Cell Biol Int. 2013 Jan;37(1):47-53. doi: 10.1002/cbin.10011. Epub 2012 Dec 4.

PMID:
23319321
[PubMed - indexed for MEDLINE]
13.

MiR-155 inhibits the sensitivity of lung cancer cells to cisplatin via negative regulation of Apaf-1 expression.

Zang YS, Zhong YF, Fang Z, Li B, An J.

Cancer Gene Ther. 2012 Nov;19(11):773-8. doi: 10.1038/cgt.2012.60. Epub 2012 Sep 21.

PMID:
22996741
[PubMed - indexed for MEDLINE]
14.

Role of p53 in the induction of cyclooxygenase-2 by cisplatin or paclitaxel in non-small cell lung cancer cell lines.

Duarte ML, de Moraes E, Pontes E, Schluckebier L, de Moraes JL, Hainaut P, Ferreira CG.

Cancer Lett. 2009 Jun 28;279(1):57-64. doi: 10.1016/j.canlet.2009.01.021. Epub 2009 Feb 13.

PMID:
19217709
[PubMed - indexed for MEDLINE]
15.

Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature.

Barr MP, Gray SG, Hoffmann AC, Hilger RA, Thomale J, O'Flaherty JD, Fennell DA, Richard D, O'Leary JJ, O'Byrne KJ.

PLoS One. 2013;8(1):e54193. doi: 10.1371/journal.pone.0054193. Epub 2013 Jan 17.

PMID:
23349823
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

The role of thymidylate synthase and dihydropyrimidine dehydrogenase in resistance to 5-fluorouracil in human lung cancer cells.

Oguri T, Achiwa H, Bessho Y, Muramatsu H, Maeda H, Niimi T, Sato S, Ueda R.

Lung Cancer. 2005 Sep;49(3):345-51.

PMID:
15993511
[PubMed - indexed for MEDLINE]
17.

Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer.

Oliver TG, Mercer KL, Sayles LC, Burke JR, Mendus D, Lovejoy KS, Cheng MH, Subramanian A, Mu D, Powers S, Crowley D, Bronson RT, Whittaker CA, Bhutkar A, Lippard SJ, Golub T, Thomale J, Jacks T, Sweet-Cordero EA.

Genes Dev. 2010 Apr 15;24(8):837-52. doi: 10.1101/gad.1897010.

PMID:
20395368
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

MRP is frequently expressed in human lung-cancer cell lines, in non-small-cell lung cancer and in normal lungs.

Giaccone G, van Ark-Otte J, Rubio GJ, Gazdar AF, Broxterman HJ, Dingemans AM, Flens MJ, Scheper RJ, Pinedo HM.

Int J Cancer. 1996 Jun 11;66(6):760-7.

PMID:
8647646
[PubMed - indexed for MEDLINE]
19.

In vitro and in vivo inhibitory effect of the combination of Wenxia Changfu formula [see text] with cisplatin in non-small cell lung cancer.

Ji XM, Ouyang B, Liu H, Liu GW, Wu ZC, Yu HY, Wang CY, Wang ZX, Wang WP.

Chin J Integr Med. 2011 Dec;17(12):908-16. doi: 10.1007/s11655-011-0933-6. Epub 2011 Dec 3.

PMID:
22139542
[PubMed - indexed for MEDLINE]
20.

Upregulation of microRNA-451 increases cisplatin sensitivity of non-small cell lung cancer cell line (A549).

Bian HB, Pan X, Yang JS, Wang ZX, De W.

J Exp Clin Cancer Res. 2011 Feb 17;30:20. doi: 10.1186/1756-9966-30-20.

PMID:
21329503
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk